184 related articles for article (PubMed ID: 37509321)
1. Optimization of Radiolabeling of a [
Winter G; Hamp-Goldstein C; Fischer G; Kletting P; Glatting G; Solbach C; Herrmann H; Sala E; Feuring M; Döhner H; Beer AJ; Bunjes D; Prasad V
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509321
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Fasslrinner F; Stölzel F; Kramer M; Teipel R; Brogsitter C; Morgner A; Arndt C; Bachmann M; Hänel M; Röllig C; Kotzerke J; Schetelig J; Bornhäuser M
Biol Blood Marrow Transplant; 2020 Apr; 26(4):691-697. PubMed ID: 31730919
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
[TBL] [Abstract][Full Text] [Related]
8. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D; Buchmann I; Duncker C; Seitz U; Kotzerke J; Wiesneth M; Dohr D; Stefanic M; Buck A; Harsdorf SV; Glatting G; Grimminger W; Karakas T; Munzert G; Döhner H; Bergmann L; Reske SN
Blood; 2001 Aug; 98(3):565-72. PubMed ID: 11468151
[TBL] [Abstract][Full Text] [Related]
9. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy for hematopoietic cell transplantation.
Jurcic JG
Immunotherapy; 2013 Apr; 5(4):383-94. PubMed ID: 23557421
[TBL] [Abstract][Full Text] [Related]
11. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
[TBL] [Abstract][Full Text] [Related]
12. Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia.
Neumaier B; Mottaghy FM; Buck AK; Glatting G; Blumstein NM; Mahren B; Vogg AT; Reske SN
Cancer Biother Radiopharm; 2008 Dec; 23(6):819-24. PubMed ID: 19111052
[TBL] [Abstract][Full Text] [Related]
13. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
14. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.
Kletting P; Maaß C; Reske S; Beer AJ; Glatting G
PLoS One; 2015; 10(5):e0127934. PubMed ID: 26010360
[TBL] [Abstract][Full Text] [Related]
16.
Tuazon SA; Sandmaier BM; Gooley TA; Fisher DR; Holmberg LA; Becker PS; Lundberg SJ; Orozco JJ; Gopal AK; Till BG; Coffey DG; Nartea ME; Matesan MC; Pagel JM; Rajendran JG; Press OW; Bensinger WI; Green DJ
Bone Marrow Transplant; 2021 Jan; 56(1):202-209. PubMed ID: 32710011
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.
Mawad R; Gooley TA; Rajendran JG; Fisher DR; Gopal AK; Shields AT; Sandmaier BM; Sorror ML; Deeg HJ; Storb R; Green DJ; Maloney DG; Appelbaum FR; Press OW; Pagel JM
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1363-8. PubMed ID: 24858425
[TBL] [Abstract][Full Text] [Related]
18. Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
Orchard K; Langford J; Guy M; Lewis G; Michopoulou S; Cooper M; Zvavamwe C; Richardson D; Lewington V
Bone Marrow Transplant; 2024 Jun; ():. PubMed ID: 38867006
[TBL] [Abstract][Full Text] [Related]
19. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.
Bunjes D
Leuk Lymphoma; 2002 Nov; 43(11):2125-31. PubMed ID: 12533037
[TBL] [Abstract][Full Text] [Related]
20. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
